Communicating effectively with the patient and family about treatment options for prostate cancer

Elisabeth Kunkel, R. E. Myers, P. L. Lartey, O. Oyesanmi

Research output: Contribution to journalReview articlepeer-review

13 Scopus citations


To help the patient with prostate cancer, his family, and his friends, in coping with the diagnosis and its treatment, health care providers need to understand the controversies about treatment options and the impact that such controversies have on medical decision-making. To update health care providers, the authors reviewed all pertinent citations in the medicine database from 1966 to 2000, and in other relevant publications. These resources are also available to our patients through the Internet and other avenues, such as books and magazines. It is the role of the physician to counsel patients about their individual circumstances to allow them to make the best individualized treatment option. Patients who have appropriate information and are actively involved with the decision-making process are, in general, psychologically healthier. Though watchful waiting has no side effects, men must cope psychologically with issues of long-term cancer survivorship. With early detection, men can choose between different treatment options (eg, radiation versus radical prostatectomy). Urinary incontinence, sexual dysfunction, and fatigue are major emotional and physical stressors for this population. Providers of care need to be aware of the psychosocial sequelae of prostate cancer and treatment-related side effects and assist their patients in processing ever-growing data on the management of prostate cancer that technology brings. (C) 2000 by W.B. Saunders Company.

Original languageEnglish (US)
Pages (from-to)233-240
Number of pages8
JournalSeminars in Urologic Oncology
Issue number3
StatePublished - 2000

All Science Journal Classification (ASJC) codes

  • Urology


Dive into the research topics of 'Communicating effectively with the patient and family about treatment options for prostate cancer'. Together they form a unique fingerprint.

Cite this